{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:25:13Z","timestamp":1768411513171,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prnil.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T02:40:13Z","timestamp":1736563213000},"page":"142-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancer"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5278-1935","authenticated-orcid":false,"given":"Alice","family":"Thomson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidar","family":"Al Saffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Tempo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10437","key":"10.1016\/j.prnil.2025.01.003_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.prnil.2025.01.003_bib2","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.21037\/tau-20-1118","article-title":"Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer\u2014a narrative review","volume":"10","author":"Ong","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"16","key":"10.1016\/j.prnil.2025.01.003_bib3","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.prnil.2025.01.003_bib4","doi-asserted-by":"crossref","first-page":"8626","DOI":"10.3390\/curroncol29110680","article-title":"Utilization trends of novel hormonal agents in metastatic castration-resistant prostate cancer in Quebec","volume":"29","author":"Hu","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2025.01.003_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/21681805.2018.1426039","article-title":"Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden","volume":"52","author":"Franck Lissbrant","year":"2018","journal-title":"Scand J Urol"},{"issue":"4","key":"10.1016\/j.prnil.2025.01.003_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.prnil.2025.01.003_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.prnil.2025.01.003_bib10","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.prnil.2025.01.003_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.prnil.2025.01.003_bib12","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prnil.2025.01.003_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","author":"Saad","year":"2024","journal-title":"J Clin Oncol [Internet]"},{"issue":"4","key":"10.1016\/j.prnil.2025.01.003_bib14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/JU.0000000000000443","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"202","author":"Fizazi","year":"2019","journal-title":"J Urol"},{"issue":"26","key":"10.1016\/j.prnil.2025.01.003_bib15","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.prnil.2025.01.003_bib16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.prnil.2025.01.003_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.prnil.2025.01.003_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdt571","article-title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","volume":"25","author":"Sternberg","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prnil.2025.01.003_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5534\/wjmh.200113","article-title":"Trends in end-of-life resource utilization and costs among prostate cancer patients from 2006 to 2015: a nationwide population-based study","author":"Ha","year":"2021","journal-title":"World J Men\u2019s Health"},{"issue":"1","key":"10.1016\/j.prnil.2025.01.003_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.prnil.2022.08.003","article-title":"Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study","volume":"11","author":"Park","year":"2023","journal-title":"Prostate Int"},{"key":"10.1016\/j.prnil.2025.01.003_bib21","first-page":"1","article-title":"Trends in incidence of metastatic prostate cancer in the US","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.prnil.2025.01.003_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of followup in the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.prnil.2025.01.003_bib23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"issue":"10231","key":"10.1016\/j.prnil.2025.01.003_bib24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.prnil.2025.01.003_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/21681805.2021.1936626","article-title":"Real world treatment utilization patterns in patients with castration-resistant prostate cancer","volume":"55","author":"Vigneswaran","year":"2021","journal-title":"Scand J Urol"},{"issue":"12 December","key":"10.1016\/j.prnil.2025.01.003_bib26","first-page":"1","article-title":"Observational study on time on treatment with abiraterone and enzalutamide","volume":"15","author":"Fallara","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.prnil.2025.01.003_bib27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","article-title":"Real-world treatment trends among patients with metastatic castration-sensitive prostate cancer: results from an international study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.prnil.2025.01.003_bib28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"Journal of Urology"},{"key":"10.1016\/j.prnil.2025.01.003_bib29","article-title":"Cancer in the Northern Territory 1991-2015: incidence and mortality","author":"Zhang","year":"2020","journal-title":"Darwin"},{"issue":"7","key":"10.1016\/j.prnil.2025.01.003_bib30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/imj.15419","article-title":"Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (mRCC) in Australia","volume":"51","author":"Balasubramanian","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.prnil.2025.01.003_bib31","article-title":"Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study","volume":"14","author":"Tang","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"10.1016\/j.prnil.2025.01.003_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bju.15699","article-title":"Impact of the COVID-19 pandemic on the diagnosis and treatment of men with prostate cancer","volume":"130","author":"Nossiter","year":"2022","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.prnil.2025.01.003_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/13696998.2019.1705313","article-title":"Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy","volume":"23","author":"Shah","year":"2020","journal-title":"J Med Econ"},{"issue":"9","key":"10.1016\/j.prnil.2025.01.003_bib34","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.21037\/tau-22-191","article-title":"Significant financial differences of chemical and surgical androgen deprivation in a contemporary cohort","volume":"11","author":"Paul","year":"2022","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.prnil.2025.01.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.7161.1","article-title":"Validating the use of medicare Australia billing data to examine trends in skin cancer","volume":"4","author":"Perera","year":"2015","journal-title":"F1000Res"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:29:53Z","timestamp":1757543393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888225000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2287888225000030"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.01.003","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}